248 related articles for article (PubMed ID: 19834313)
1. Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.
Moran LJ; Meyer C; Hutchison SK; Zoungas S; Teede HJ
J Endocrinol Invest; 2010 Apr; 33(4):258-65. PubMed ID: 19834313
[TBL] [Abstract][Full Text] [Related]
2. Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome.
Hutchison SK; Harrison C; Stepto N; Meyer C; Teede HJ
Diabetes Care; 2008 Jul; 31(7):1427-32. PubMed ID: 18390799
[TBL] [Abstract][Full Text] [Related]
3. Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome.
Glintborg D; Mumm H; Altinok ML; Richelsen B; Bruun JM; Andersen M
J Endocrinol Invest; 2014 Aug; 37(8):757-764. PubMed ID: 24906976
[TBL] [Abstract][Full Text] [Related]
4. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
5. Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS.
Burchall GF; Piva TJ; Ranasinha S; Teede HJ
Thromb Haemost; 2017 Nov; 117(11):2053-2062. PubMed ID: 29202210
[No Abstract] [Full Text] [Related]
6. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
Li M; Yang M; Zhou X; Fang X; Hu W; Zhu W; Wang C; Liu D; Li S; Liu H; Yang G; Li L
J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380
[TBL] [Abstract][Full Text] [Related]
7. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
8. L:A ratio, Insulin resistance and metabolic risk in women with polycystic ovarian syndrome.
Gupta V; Mishra S; Mishra S; Gupta V
Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S697-S701. PubMed ID: 28529126
[TBL] [Abstract][Full Text] [Related]
9. Adiponectin and leptin in overweight/obese and lean women with polycystic ovary syndrome.
Chen CI; Hsu MI; Lin SH; Chang YC; Hsu CS; Tzeng CR
Gynecol Endocrinol; 2015 Apr; 31(4):264-8. PubMed ID: 25423261
[TBL] [Abstract][Full Text] [Related]
10. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO
Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
[TBL] [Abstract][Full Text] [Related]
11. Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations--introductory report.
Marciniak A; Nawrocka-Rutkowska J; Brodowska A; Sienkiewicz R; Szydłowska I; Starczewski A
Folia Histochem Cytobiol; 2009; 47(2):323-8. PubMed ID: 19995720
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls.
Glintborg D; Andersen M; Hagen C; Frystyk J; Hulstrøm V; Flyvbjerg A; Hermann AP
Eur J Endocrinol; 2006 Aug; 155(2):337-45. PubMed ID: 16868149
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
14. The impact of metformin treatment on adiponectin and resistin levels in women with polycystic ovary syndrome: a prospective clinical study.
Basios G; Trakakis E; Chrelias Ch; Panagopoulos P; Vaggopoulos V; Skarpas P; Kassanos D; Dimitriadis G; Hatziagelaki E
Gynecol Endocrinol; 2015 Feb; 31(2):136-40. PubMed ID: 25377599
[TBL] [Abstract][Full Text] [Related]
15. Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS)--the effect of metformin treatment.
Kruszyńska A; Słowińska-Srzednicka J; Jeske W; Zgliczyński W
Endokrynol Pol; 2014; 65(1):2-10. PubMed ID: 24549596
[TBL] [Abstract][Full Text] [Related]
16. Endocrine and metabolic characteristics in polycystic ovary syndrome.
Glintborg D
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
[TBL] [Abstract][Full Text] [Related]
17. The adiponectin-to-leptin ratio in women with polycystic ovary syndrome: relation to insulin resistance and proinflammatory markers.
Xita N; Papassotiriou I; Georgiou I; Vounatsou M; Margeli A; Tsatsoulis A
Metabolism; 2007 Jun; 56(6):766-71. PubMed ID: 17512308
[TBL] [Abstract][Full Text] [Related]
18. Chemerin as a marker of body fat and insulin resistance in women with polycystic ovary syndrome.
Kort DH; Kostolias A; Sullivan C; Lobo RA
Gynecol Endocrinol; 2015 Feb; 31(2):152-5. PubMed ID: 25295622
[TBL] [Abstract][Full Text] [Related]
19. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
20. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
Meyer C; McGrath BP; Teede HJ
Diabetes Care; 2007 Mar; 30(3):471-8. PubMed ID: 17327307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
